Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS

The Oral Ganciclovir European and Australian Cooperative Study Group*

Objectives: To evaluate the efficacy and safety of oral ganciclovir for the maintenance treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.

Design: A 20-week, randomized, multicentre, open-label study. Progression of retinitis was assessed by funduscopy and masked reading of fundus photographs.

Methods: Adult patients with AIDS and stable CMV retinitis following a 2-3-week induction course of intravenous ganciclovir (5 mg/kg every 12 h) were randomized 2:1 to receive maintenance therapy with oral ganciclovir 500 mg six times daily, or 5mg/kg intravenous ganciclovir once daily infused over 1 h. The primary efficacy variable was time to progression of CMV retinitis from initiation of maintenance therapy.

Results: A total of 159 patients were enrolled; 112 received oral ganciclovir and 47 intravenous ganciclovir. By masked assessment of fundus photographs, CMV retinitis progressed in 72% of patients in the oral group and 76% in the intravenous group. Mean time to progression was 51 days with oral ganciclovir and 62 days with intravenous ganciclovir *(P=0.15)*. By funduscopy, CMV retinitis progressed in 59% of oral ganciclovir patients and 43% of intravenous ganciclovir patients. Mean time to progression was 86 and 109 days, respectively (P=0.02). Diarrhoea and neutropenia (absolute neutrophil count <500x 10^6/l) were the most frequently reported adverse events in both groups. The incidence of sepsis for the oral and intravenous ganciclovir patients was 3 and 8.5%, respectively. Infection at the intravenous site occurred in 0 and 9% of patients, respectively.

Conclusions: Oral ganciclovir offers an effective *and* safe alternative to intravenous ganciclovir in the maintenance therapy of CMV retinitis.

AIDS 1995, 9:471-477

Keywords: Oral ganciclovir, cylomegalovirus retinitis, AIDS

Introduction

Cytomegalovirus (CMV) retinitis is the most common opportunistic ophthalmic infection in patients with AIDS II], with the incidence ranging from 20 to 34% in adult patients with AIDS 12-61. If untreated, CMV retinitis results in retinal necrosis and eventually in permanent loss of vision 12,3). As the life expectancy of HIV patients increases with improved pharmacologic intervention, morbidity from CMV retinitis may also be expected to increase.

Intravenous ganciclovir has been shown to be effective in controlling retinitis and in halting its progression 17-•111. The dosage regimen is an initial high dose (induction) for 2-3 weeks followed by lower doses (maintenance)

!See Appendix for details.

Sponsorship: Supported by Syntex Research, Maidenhead, England, UK.

Requests for reprints to: Sven Danner, MD, PhD, Department of Internal Medicine, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Date of receipt: 3 October **1994; revised:** 6 February 1995; accepted: 14 February 1995.

for an extended period. The recommended induction dose is 5 mg/kg infused at a constant rate over 1 h, every for 14-21 days. The maintenance dose is 5 mg/kg infused over I Is daily on 7 days per week, or 6mg/kg once daily on 5 days per week.

An oral form of ganciclovir has been developed which may prove to be more acceptable for maintenance therapy of CMV retinitis than the intravenous formulation. The safety and bioavailability of oral ganciclovir in doses ranging from 1000 to 6000 mg daily have been assessed in a pilot study of 69 patients with AIDS who were shedding CMV (n =19) or had received more than 4 weeks of prior intravenous ganciclovir therapy (n =50) (121. Oral ganciclovir was shown to have relatively low bioavailability (6"%) but had prolonged absorption from the gastrointestinal tract. A dose of oral ganciclovir of 3000 mg daily **was well** tolerated and yielded plasma concentrations of ganciclovir with an average concentration of between 05 and 1.0µg/ml . Within this concentration range, ganciclovir exceeds the median ***in vino*** inhibitory concentration (ICso) of most CMV clinical isolates (13(.

The purpose of the present study **was** to compare the efficacy and safety of a 3000 mg total daily dose of oral ganciclovir with the recommended intravenous ganciclovir dose (5 mg/kg daily) for maintenance treatment of CMV retinitis in AIDS patients.

Subjects and methods

Patients were enrolled into the study in 12 sites in Europe and Australia. Patients were at least 18 years of age, had AIDS and CMV retinitis which had achieved remission or stabilization (i.e., lesions were not progressing or were totally inactive) following a 2-3 week induction course of intravenous ganciclovir (5 mg/kg every 12 h). Patients were excluded from entering the study if they had more than three induction courses of any anti-CMVtherapy, **clinical manifestations** of CMV disease requiring additional treatment, Karnof performance score <50%, significant gastrointestinal signs and sympdiscontinued solute neutrophil count (ANC) <750x 10^6/I. platelet count <50x 10^9/I, creati clearance <70ml/nsin per 1.73ns^2, or ala- ' aminotransferase levels > 2251U. All patients gave written imfonned consundus the procedures followed were in accordance with the 1975 Helsinki Declaration, as revised its 1983.

Patients entering the study were randomized in a 2: 1 ratio to receive 20 weeks of maintenance therapy with either oral ganciclovir 500 ung six times daily during waking hours (preferably with a snack or meal), or 5mg/kg intravenous ganciclovir given once daily over I h. Maintenance thof bilateral d ' after the 2-3 week induction course ofmost venous ganciclovir. Patients who had never received anti-CMV therapy other than the one induction course of intravenous ganciclovir that '..... finely preceded this maintenance study were considered 'naive' and were randomized separately f those patients who had a previous history of induction treatment for CMV retinitis. The following medications were not permitted during treatment: selected antimetabolites and alkylating agents, acyclovir for prophylaxis, foscansct, CMV hyperimmune globulin, and insipeneut-cilastatin. Neomycin, vincristine, and vinblastine were permitted anti-CMV therapy f Kaposi's sarcoma. Zidovudine (ZDV; up to 600 tag daily), didanosine (ddl) or zalcitabine (ddC), and oral or intravenous acyclovir for the treatment of herpes simplex infection, were permitted for periods tip to 14 days.

Physicreatinine aminati70ml/min ratory1.73m2 ions and ophthalmological examinations were performed at baseline, and ainformede 1-11V disease history was taken. Patients were assessed every 2 weeks throughout the study ***for*** Karnofsky score, physical and ophthalmological examinations, diarrhoeal status, blood tests (haematology and biochemistry), and the occurrence of adverse events. CD4+ lymphocyte count (absolute and percentage) was measured at baseline and at the end of treatment. The protocol did not include any virological assessmimediately i the patients.

Efficacy assessments

The primary efficacy variable was time to progression of CMV retinitis from initiation of maintenance therapy. Ophthalmological xaminations included best corrected vision. slit-lamp examination, dilated f Ins examination, and serial rondos photography. Clinical assessment of CMV progression was made by direct visualization and photographic assessment. Although this was an open-label study, treatment efficacy as dete I by fundus photography was foscarnet central reading of the photograpimipenem-cilastatini versity of Wisconsin (Madison, Wisconsin, USA). Progression of CMV retinitis was defined in the protocol as evidence of a new, discrete lesion of CMV retinitis in a previously uninvolved area of the rondos of either eye, or an advancement of the edge of any existing lesion of CMV retinitis by one-half disc diameter or by 2 750 µms. If CMV retinitis progressed as assessed by funduscopy, the patient was discont' d from die study but seen again at 20 weeks from the start of treatment. All patient management decisions were made by asked practitioners on the basis of results from funduscopic evaluations. FPundus photographs were read centrally by a single, unasked practised observer after the clinical phase of the study was completed.

Additional analyses for time to progression were conducted between various subgroups: naive/non-naive status, use of concomitant antiretrovirals, and the use of concomitant ddl. Comparisons were made between the study treatment groups for time to development ofbilateral disease and progression into zone 1 (the mssDst central part of the retina) from the start of maintenance. Changes in visual acuity (i.e.. improvement, stabilization

or deterioration) were recorded as compared with baseline assessments.

Clinical outcomes assessment included the development of extraocular CMV disease, herpesvirus infections, and changes in Karnofsky performance scores.

Safety assessments

Safety **was** assessed by laboratory tests and **monitoring** clinical adverse events. Laboratory tests included haemoglobin, haematocrit, red blood cell count, white blood cell count. differential count. platelets, and se biochemistry. All adverse events were reported regardless of severity and relationship to study medication. Adverse events were categorized according to body system and preferred term within body systems. All patients were included in the analyses of safety data.

Statistical analysis

Time to progression of CMV retinitis, assessed by and fundus photography, was estimated using Kaplan—Meier methods and treatments were compared using die log-rank test. The difference between treatment groups in relation to mean time to progression **was** quantified by 95% confidence intervals (CI) calculated using normal approximations to die distribution of the Kaplan—Meier estimates of the mean times to progression. All statistical tests were two-tailed and carried out at the 5% significance level. Estimates of miscast and median tines to progression were obtained front the estimated survival functions.

Results

Patients

A total of 159 patients were enrolled in the study and randomized to receive oral (n =112) or intravenous ganciclovir (n =47). Demographic and baseline disease characteristics are shown in Table I. The majority of patients men. Only 10 women participated in the trial, and all, by **chance**, received oral ganciclovir. The study design did not include any stratification by sex and the women were from six different centres. For all patients. the time from first diagnosis of CMV retinitis to entering the study ranged from 0 to 41 months (mean. 2.5 and 1.3 months for oral and intravenous, respectively). The group mean for patients receiving oral ganciclovir was probably skewed by a single high value of 41 months (median, 1 month for both groups). The miscast duration of the previous induction course with intravenous ganciclovir was 18.6±3.6 days in the oral group and 18. I ± in the intr**avenous** group. All other demographic and baseline disease characteristics were s lar *for* both treatment groups.

Funduscopic data were available for 154 of the 159 patients enrolled and data from 141 patients **were** included in evaluations of Condos photographs. Vaseline fundus photographs were available for 130 patients. For the

Table 1. Demographic data and baseline disease characteristics.

	Oral ganciclovir In=112)	Intravenous gancickwir (n = 47)	
Age (years)			
Mlvn (range)	38.6(23-58)	39.4(25-62	0.57'
Race(%)			
White	95 (85)	45 (96)	0.35 [1]
Black	2(2)	1(2)	
Other	15(131	I(2)	
Sex Wale/female)	102/10	47/0	O.Oit
Kauwlsky sr Ne			
Mean 1 Si)	80.4 113.7	77.8114.0	0.28'
CD4 r cell count (x 10^6/1)			
Mean (range.)	21.1 (0-320)	18.5(0-1001	0.604
Months with AIDS			
mean :So	14.8 312.2	17.9114.6	0.17'fundus
Months since CMV retinitis diagnosis			
mean SD	2.536.1	1.312.1	0.064
No. induction causes 1%)			
1	87(78)	40(85)	t).41 [1]
2	15(13)	4(9)	
3	10(9)	3 (6)	

'Sludcnrs I IIV. ION Kran-Mantel-4laenszel test. [1F] isher's exact test. tStudent's t lest adjusted for unequal variances. CMV, cytlnegalo. virus.

11 patients with no baseline photIntravogusphs fu ddus, s photographs from the first available visit were used as baseline. AccordinRetinitis uscopic examinations. all evaluable patientdetachment/fment MV retinitis at baseline (Table 2). In contrast, according to fimdus photography, etinitis was active (but not progressing and therefore considered stable) in exact eyes of 82 (87%) patients in the oral group and 28 (78%) patients in the intravenous group at baseline. All patients entered in the study *were* evaluated for safety.

Table 2. haselirr ophthalmic characteristics.

	% Patients		
	Oral ganciclovir (n=110	Imravenous ganciclovir ganciclovir	'
Unilateral retinitiMean		77	0.25'
Relinilis in ewe I I	42 (46)	34 (47)	0.161(1.0'1
Retinal dewamale/female			0.58'
Retinal tear	3	0	0.56'
Macular oedema	II	16	0.42'
Disc swelling	13	**14**	I.ts)'1,00
Visual acuity of 6112 **or** better			
Wase eye	84	77	
Vetter eye	99	98	

'I Met exac l Inst. IV,111n s in paft-11111C M'S irx hr **ale rCSlrl1S !NtsCd on (tondos I d wsogsaph. ICN Nan.** Maine1 - i lacnszel less.

Twenty (18%) out of 112 patients completed 20 weeks of treatment with oral ganciclovir and 19 (40%) out of 47

completed 20 weeks with intravenous ganciclovir. Sixty-*four* patients (57%) in the oral group and 15 (32%) in the intravenous group **were** discontinued using funduscopic evidence of progression. Sixteen (14%) patients in the oral group and seven (15%) in the intravenous group discontinued treatment because of adverse events.

Progression of CMV retinitis

Fundus photographs indicated that CMV retinitis progressed in 72% (75 out of 104) of patients in the oral group and in 76% (28 out of 37) of patients in the intravenous group. The mea[tims from the start of main-**tenance** to the first progression of retinitis was 51 days (median, 41 slays) in the oral gimp and 62 days (median, 60 slays) in the intravenous treatment group, a difference of I 1 days between die two survival curves (1'=0.15) by log-rank test. The percentage of patients remaining free from progression at each time from the start of , determined by fundus photographs, is shown in Fig. 1. Based on photographic **assessment,** the 95% CI for the **mean difference** in time to progression was between -24 and 1 day, indicating that there is a 95% chance that the true **mean time to** progression for oral ganciclovir treatment was not more than 24 days earlier or 1 day later than the true mean time to progression for intravenous ganciclovir treatm eat.



Mt nnOM SIMIto rionw..ct OtAloH)alit

fig. 1. Prop onion of patients remaining free from progression at each tint horn 1 to start of maintenance as determined by fundus photographs a» assessments (Kaplan-Meier estimates). (0), ()rat gancic mor(group (n=104); **CI,** intravenous ganci-clovir gaup (n=37). *P*= 0.15 by log-rank comparison test.

Based on funduscopy, CMV retinitis progressed during maintenance in 59% (65 out of 110) of patients in the oral ganciclovir group and 43% (19 out of 44) of patients in the intravenous group (Table 3 and Fig. 2). The **mean trout the start of maintenance treatment to** the first progression of retinitis was 86 slays (median, 84 days) in the oral treatment group and 109 days (median, 137 days) in die intravenous treatmem group, a difference of 23 days between the two Kaplan-Meier curves (P=0.02, log-rank test).

Progression in naive versus non-naive patients

According to I.....luscopy, the mcan time to progression for **naive** patients **was** 91 days for patients in the **oral** group and 109 days for patterns in the intravenous **group** (P=0.09). By fundus photographic assessment,

Sable 3. line to initial progression of cyonmegalovirus retinitis.

	aal ganciclovir	Intoral/intravenousvir	
fwnfus opy assessment (n)	110	44	0.02
No. patients progressing (%)	65159)	19143)	
Mean days (Si?.))	85.9(4.5)	108.7 (6.8)	
Median days (95% CO	84(68-98)	13701C)	
oi(kvence between um0fieravenaus means (95% CI)	-21(-39 to -7)		
Photographic **asSesuprogressi**on		37	0.15
No. patients progressing (%)	75(72)	28(76)	
Mean days (determined	3)	6215.1)	
Median days (95% CI)	41(31-45)	60(42-83)	
Difference between **otaU/mtraVe'nous nears** (95% CI)	-111-24 to I)		

'Value (or **treatment comparisons. CI,** confidence interval; NC, nut calculable.



fig. 2. Proportion of patients remaining free from progression at rom the start of maintenance as deter-**Milled** by funduscopy assessments (Kaplan-Meier estimates). K)), Oral ganciclovir group (n =110); **41,** intravenous ganciclovir group (n=44). *P*= 0.02 by log-rank comparison test.

mean .....'s CO progression were 54 days in the oral group and 64 slays in the intravenous group *(P=0.22).* **ll'im** to progression for non-naive patients were shorter than those for naive patients. The **trrea**n were 65 and 93 days, respectively, for the oral treatment enous groups according to funduscopy (P=0.21) and 37 and 38 days, respectively, according to photographic evaluations (P=0.96).

Progression in patients taking concomitant antiretrovirals

Fifty per cent (22 out of 44) of patients its the intravenous gancic group and 62% (68 out **of 109)** of patients in the oral ganciclovir group received one or more antiretroviral agents during ganciclovir maintenance treauttent. By photographic assessment, neat time to progression for patients who received concomitant antiretrovirals were 48 and 73 days for oral and intravenous ganciclovir, respectively (P=0.02); for patients who slid nofu**ndus icopy** concomitant antiretrovirals, **mean tints to** progression was 54 days and 47 days, respectively *(P=0.35).* Direct funDifference assessmen an **timte** to progression fix patients who rec comitant antiretrovirals as 86 and 127 days for oral and intravenous ganciclovir, respectively (P=0.0009); for patients who did not receive concomitant antiretrovirals,

Mean Lime to progression Was 85 days for both I treatment groups.

ddl was used by more patients than either ZDV or ddC. In patients receiving ddl together with ganciclovir, mean time to progression by photographic assessment was 45 and 71 days in the oral and intravenous ganciclovir groups, respectively (1'=0.04). Mean time to progression by funduscopic assessments was 83 and 128 days in the oral and intravenous ganciclovir groups, ***(P=0.01).***

Other ophthalmologic evaluations

Visual aeuity remained stable during maintenance treatment for the majority of patients. Visual acuity deteriorated in 16% (18 out of 110) of patients in die oral ganciclovir group and in 11% (five out of 44) of patients in the intravenous ganciclovir group ***(P=0.29).***

Eleven per cent (eight out of 74) of patients its the oral ganciclovir group and 12% (four out of 34) of patients in the intravenous group progressed from unilateral to bilateral retimtis during maintenance treatment, as assessed by . Mean times to progression were comparable. 125 and 122 days in the oral and intravenous groups. respectively. Photographic assessment showed that 10% (seven out of 70) of oral ganciclovir-treated patients and 19% (six out of 31) of intravenous ganciclovir-treated patients progressed to bilateral disease. Mean time to progression by photographic assessment was 42 days in the oral group and 74 days in the intravenous group. The difference between the treatment groups for time to progression to bilateral disease was not statistically significant ***(P=0.55).***

Time to progression of CMV retinitis into zone 1 from other parts of the retina was also assessed by both funduscopy and fundus photographs. According to assessment, 12% (12 out of 103) of patients in the oral group and 7% (three out of 43) of patients in the intravenous group showed progression into zone 1. Mean time to progression was 125 days in the oral group and 121 days in the intravenous group ***(P=0.16).*** Fundus photography indicated that retinitis progressed into zone 1 in 1% (one out of 86) of patients in the oral group and in 3% (one our of 33) of patients in the intravenous group.

Clinical outcome

New episodes of extraocular CMV disease, herpes simplex virus infections, and herpes zoster infectious occurred in only three patients (2%) throughout the study. One patient taking oral ganciclovir developed new disseminated CMV disease. none of the patients developed new herpes simplex infectious, and only one patient in each treatment group reported a new episode of herpes zoster infection. Three (6.4%) of the intravenous ganciclovir group and four (3.6%) of the oral group received acyclovir. Karnofsky performance scores were generally hanged from baseline at all the study visits.

Safety

The majority of patients its both treatment groups reported an adverse event; there were no significant in incidence or type of adverse *event* between groups». The must frequently reported adverse evens were diarrhoea and neutropenia ***(fable** 4)*; neutropenia (AN(: <50(1x 10^6/I) occurred mole frequently in the intravenous compared with the oral ganciclovir group (23 versus 14%, respectively; ***P=0.23)*** and diarrhoea **occurred** more frequently its the oral ganciclovir group compared with the intravenous ganciclovir group (33 versus 21%, respectively; P=0.18). Anaemia (haemoglobin <9.5g/dl) occurred equally in both groups (40% intravenous, 36% oral). The incidence of thrombocytopenia (platelet count <50 x 10^9/1) was also similar in both groups *(9%* intravenous, 7% oral).

Table 4. Advert events.

	No. patient> (9)		
	Or hal galn icl (ri	111a(av am. is kivit (1i =47)	
All advert ...vents	91 (81)	41 (87)	
Neutropenia•	15(14)	10(23)	0.15
Ihranlxxylupsuial	7 (7)	4 (9)	
At.al.,ni mI	38 (361	17 (40)	
Dmndwea	17 01)	10121)	0.18
I evert	15(14)	9119)	
Asalmost	1 I (10)	4 (6)	
Atxkx11111J1 pain	13(12)	2 (4)	
Kash	11 (10)	0	
Sepsis	4 (3)	4 (8.5)	***0.10***
Infection at intravenous nt	0	4 *el)*	

Nemiluope ia, Ilxanlxvcyallpeitia, 41114 ia bate) WI 41 anal 107 patienUnfortuately la y data. •Absolute lieumaglhil i Emma <5(x1x 10^4/I. Irlatelet count v.50x 10 ·/I. 11 latvisnsl4un <').Sg/dl. tllaxd al 44 1.aIiaof.

idence of sepsis was alnwst three times greater in the intravenous group than the oral group (8.5 versus 3%; P=0.20). hnfection at the intravenuus site also saccurred more Often its ***die*** intravenous group (9%) compared with the oral group (0%). Unlisrtuuately, no information was specifically collected eonce g the presence ganciclovir ral venous catheter patients Taking oral ganciclovir. hash was also reported more frequently in **the oral** group than the intravenous group (10 versus 0%). It is unclear whether this is of clmutal significance.

Discussion

Untreate -related diseases are associated wadi *a* high incidence of morbidity and mortality (14). Almost a decade ago, published studies hat ganciluvir

was effective in treating CMV retinitis in patients (15.I(4. Subsequent published clinical studies of intravenous ganciclovir, administered on an induction regimen and then continuously as therapy, demonstrated that progression of retinitis could be forestalled Ion a median Of 42-I28 days (17-201. of efficacy, however, continual maintenance therapy with intravenous ganciclovir requires establishment of permanent venous access that may further a deteriorating quality of life. furthermore, a permanent, indwelling venous catheter carries the potential for sepsis and catheter-related adverse events.

Administration of ganciclovir by the oral route results in plasma concentrations that exceed the in *vireo* 1C:50 of taont CMV clinical isolates (12(. The ability to deliver an oral dose of ganciclovir that is effective in maintaining the stability of CMV retinitis, and well-tolerated, would be of significant benefit. The purpose of this 20-week study was to compare the efficacy and safety of oral ganciclovir therapy (3000 mg daily) and intravenous ganciclovir therapy (5 mg/kg daily) in maintaining the stability of CMV retinitis in patients with AIDS.

The principal efficacy parameter was time to progression of retinitis. Progression was assessed by direct funduscopic visualization d g the course of the study, and by evaluation by a masked experienced reader at the conclusion of the study. Patients withdrawing before 20 weeks *were* considered to be censored at the time of withdrawal in the analysis. Kaplan-Meier curves showing the time to progression (Fig. I) were used to evaluate treatment differences. At each timepoint , the plot shows the estimated proportion of subjects who are free from progression, from which the mean time to progression can be estimated . fu this study the mean time to progression was considered to be a more valid summary measure becausė of the 'step down' effect in the curve, which affected median but not wean values.

On the basis of masked assessment of fundus photographs, patients receiving oral ganciclovir experienced progression earlier (mean. 11 days) than patients receiving intravenous ganciclovir. Statistically, the 95% CI around the difference between the wean days to progression in the two treatment groups indicated that there is a 95% chance that the true menu to disease progression with oral ganciclovir maintenance was no core than 24 days earlier or I day later than the mean) time to progression with intravenous ganciclovir therapy. These results c ast with those obtained when progression of retinitis was determined by the evaluating (unmasked) ophthalmologist using funduscopy. This !method of assessment resulted in longer times to progression for both treaunent groups, and a statistically significant difference between time to progression with oral and intravenous ganciclovir treatmrent. While it is important to consider the results from both assessments, in the clinical trial setting, assessment of serial fundus photographs is more objective and may be a more sensitive method for determining retinitis progression. Assessment of serial Condos photographs by a masked third party removes observer bias that may skew study results, since the treating physician and the were aware of the Ire lit received by each patient. In the previously published, multicentre, clinical trial designed to compare ganciclovir and foscarnet, only masked fundus photographs were used to determine and compare times to progression (8(.

Naive patients (i.e., those who were not previously treated for CMV retinitis) had longer times to progression than iron-naive patients. This is mot unexpected since studies have shown the median tune to progression becomes shorter with each subsequent reactivation (21,22). Based on masked photographic assessment there was no difference in time to progression of CMV retinitis between oral and intravenous ganciclovir in patients who did not receive concomitant antiretrovirals. For patients who received concomitant antiretrovirals, there was a statistically significant longer time to retinitis progression among patients randomized to intravenous rather than oral ganciclovir. These saute results were reported when assessment was by direct observation via . In two similar studies of oral and intravenous ganciclovir in CMV retinitis this phenomenon has not been observed (23,241. Furthermore, if data are divided into too many subgroups, significant differences *between* the groups start to appear by chance.

As assessed by funduscopy, there was no difference between the treatment groups in the percentage of patients who developed bilateral disease during treatment, or the time to progression. I however, by photographic assessment the percentage of patients who developed bilateral disease d ' g intravenous treatment was almost twice that of orally treated patients, although the time to progression was not significantly different . Neither assessment nor fundus photographs showed significant differences in the percentage of patients with progression of retinitis into zone I.

Although the patients int this study were ill an advanced stage of 111V disease, only one new diagnosis of extraocular CMV disease was made during the study. This low incidence of extraocular CMV disease may reflect a secondary benefit of systemic CMV retinitis treatment and should be considered in discussions about types of therapy.

The majority of patients in the study experienced adverse events; however, many could be related to advanced 111V disease, opportunistic diseases, or other concomitant medication. The safety benefits of oral ganciclovir maintenance treatment included a lower incidence of sepsis and neutropenia compared with intravenous administration. Sepsis and infection at the site oceurred more often in the intravenous-treated patients (8.5% sepsis, 9% intravenous-site infection) than the orally treated patients (3% sepsis, 0% intravenous-site infection). The rate of neutropenia in the intravenous ganciclovir group was nearly doable that of the oral group, 23 versus 14%, respectively.

Based on the results of fundu**scopic and photographic assessment of progression, stability of visual acuity, progression from unilateral** to **bilateral disease and progression of retinitis into zone** I from **the remainder of (he retina, this study demonstrated that the efficacy of oral ganciclovir for maintenance treatment of CMV retinitis is comparable with intravenous ganciclovir Oral ganciclovir was well tolerated and,** as **shown by this study, has a distinct advantage over intravenous ganciclovir by** alleviating **a potential site of infection caused by the** 1111f11**venous catheter. Oral ganciclovir offers the patient and physician an alternative to intravenous administration in the maintenance therapy of CMV retinitis.**

References

I. Kulgx.-unann 111), (lures-Aguilar M, Quicwa II, ***et*** al: Combination ganciclovir and loscamel in the treatment of resistant cytontegalovirus retinitis is patients with ***acquired*** immunodeficiency syndrome. *Aids Upluhahnxtl* 1991, 111:1359-1166.

2. Koany 1D, fisher 11, Nussbaum 11; lung-term visual nsurbidily of cytoongalovirus retinitis in patients with acquired iumurse deficiency syndrome. *ONluhahnulogy* 1993, I00:I6I5-1688.

3. 1 Jutland *CN,* repose IS, **past** 111, e9 al.: Acquired immune deficiency syndronte. Ocular manifeslatiuns. *Uphilubssulugy* 1983, 90:859-873.

4. Palestine AC, Kuclsigues MM, Mather *Mt, ei al.:* Oplsllsalnsic involvement in acquired immunodeficiency syndrome. *Oph• Ihahnwlugy* 1984. 91:1092-1099.

S. I'rlxsua IS, I lulled *CN,* Nestor MS, *ei al.:* Acquired im. mune deficiency syndrome. Pathogenic mechanisnts of ocular disease. *Opinhaboslugy* 1985, 93:472-484.

6. labs **DA, Cnerr** WK, fox K, *el* a/.: Ocular nu nifeslations of acquired insure deficiency syndrome. *Ophdsabssulugy* 1989, 96:1092-1099.

7. **Koppermann** 11D, Quicessu 11, flures•Aguila M, et al.: Intravitreal ganciclovir eoncentration aller intravenous admi' lion in AIDS patients wills cytunsrgaluvirus retinitis: input''• lions for therapy. *1 Weil Dir* 1993, 168:1506-1509.

6. Studies of the Ocular Complications of AIDS Keseaa'h Coup in collaboration wills the AIDS Clinical Trials **Croup:** Mortality in patients wills acquired intmunodeficiency syndrome treated wills either **foxansei Of** gruidovir fur tylunsegduvinn retssnln. *N /ing! I Abd* 1992, 326:213-220.

9. Palesiiue AC, Stu ems Ir C, I as e I1**C, ri a1.: Tfealnnenl** of cyto. megalovirus retinitis wills dihydroxy propouymelhyl guanine. *Am I Ophrhahuol* 9116, 101:95-101.

10. labs OA, **Nse man C,** Dc Limnos 5, Polk llf: Treatment of cyto. ntegalovirus retinitis with ganciclovir. *Ophllsabnufugy 1987,* 94:824-810.

II. Itesdrdy DE, freeman WK, Causey 1)M, Rao NA: Cytomegalovirus retinitis and response to therapy wills *ganciclovir. Opts. dulnmlugy* 1987, 94:425-434.

12. Spector SA, Dosch Df, Follansbee 5, *ei al.:* Phumacokinrtic, safety and antiviral profile of oral ganciclovir in IIIV-infected persons> (ACIC 1 27). *fuss National (.'otesr:me Oss Ilusnus Keruvlrusr and Relarar! Waaliom.* Washingron, IX', Decent Icer 1993 labsuatt 5391.

13. Plotkin SA, View WI., lolsensiciu D, e9 al.: Ser>ilMay of clinical isolates of human glumrgalovirces to 9-(I,3•dihydroxy.2-propoxyuselhyl)guanlne on human cylanegalovism replication *in eilst).* J ***Sllest (As*** 1985, 152.833-814.

14. **Km AK, lied UU** Management of glwnegalusirus infection ist patients will, acquired innsuswdrticiency syndrome. (*Ira /'ham* 990, 9:611-611.

IS. Folr sssreiu t), U'Asnicu I)f, **16rxh** *AMS, el al.:* **Treamnenl** ul Cytomegalovirus retinitis will, '3.52.1sydroxy. t-thydrusyn eihyll-etlsusymselhyllguan inw. ***Arm Mur.,*** A *led* 1985 10t 17/ rtN)

16. **Ifach M(, 0agwcll SP,** Nalsp NI; *es al.:* 9•(1,3-0ibydrusy-1. proposyntelsylguanioe **for** glonegaluvirus inferno... in palienls wilt, acquired immunodeficiency syrdrunse. *Ann locus Akd* 985, 103.181••184.

17. Jacobson MA, O'Donnell noodle lit, **es** al.: Kandwnired prospective trial of gar cicluvir maintenance therapy fur glu. megalovirus retinitis. Akd *Vaud* 988, 25'319-149

18. Bullies WC, Alaslre lit biller AI, ca *al.:* Cancic low treat sent of life- **or** sigbbthrealeuing cytonegalovims idearion: experience in 314 imnunoconprunsised patient. *Kee twisr* On 1988, IU (wppl 31:5495-5506.

19. Laskin Ol, Ceelydxrg DM, Milli *ei al.:* **Ganciclovir** *fur* ***the*** treatment ***and*** suppression of serious infections caused by cytontegalovirus. Arn *J* Akd 1987, 83::101-307.

20. Holland CN, Sdslaru Y, Ksrsges At, *et al.:* Treatment of cylumegaluvinn IthImpinly **will, gatkiuvir.** *Uphllwl"u'lully* 1987, 94:815-823.

21. Osellana I, Teich SA, Friedman All, terelxasn f, Wueedaxn I, M,ldvan I): Combined shun- and long-lens therapy **list she treatment of cylwnrgaluviru «tinilis** using gauicluvir (OW 8759U). Oldxhalnwlogy 1987, 94:811-818.

22. Cross IC, **Uuatalc** SA, **Malbcm WC, ct al:** longitudinal *sludy* of epunsegaluvims retinitis in acquired inuusse deficiency syndrome. *Ophthalnxdugy* 1990, 97.681-686.

23. Sapnins KE, Slevsysien MI, Shadmmt A, 0uclds Is WC: Oral gass• cicluvir **(POC) cretin itu**venous ganeicluvir **(IVC) nwitenance** therapy fur cytomegalovirus retinitis in palienls **with** AIDS: prelinisary results of • Phase 3 study. *fuss* ***Nanoral COOMeiNY urs*** *u* ***vula., Karuvinnt, and Krlaas! bun Inuit.*** Washington, DC, Oa'rmber 1991 labslract 54(11

24. lalreasi JP: Oral vs hsltaeenons garc'iloelr (CCV) as mainleuance treatment of newly diagnosed cyto nwgaloriros « linitis (CMVK) in AIDS. **I'rexntrd** at Ilse Sc'nc.xh *Inlcorsarixnal Con. Walr". on* ***Antiviral Kaxvrs h. (Isarsemun,*** Mauls 1994.

Appendix

The Oral Ganciclovir European and Australian Cooperative Study Group comprises: *Australian: 1).* Cooper and 1'. McCloskey, St Vincent% Hospital, Sydney; *Dew stunk:* L. Malbiesen **and** K.K. Bonne, Kobenhavus 1Ividovre Hospital; P. Skiuhrl, J.U. Praise and S. Tinning, Rigshospitalet, Copenhagen; *England:* **S. Baton, St Stephen's Clinic; M. Johnson, Royal Fier: 1 hospital; J.** Main, A. Pinching. and C. Migdal, **St** Mary's 1 lospital; S. Mitchell, Moorlields Eye I lospictl, Loudon; *Frarlu:* C. Katama and I Le Iloang, I löpital Ica I'itie-Salpetrie•re; S. Malherot and I. Cochereau, I löpital Bichat-(laude-Bernard; W. Roznanbaum and L. Zazoun, I lopital Ruth - schild, Paris; *Germany:* E.M. Fabricius, Berlin; **J. Garweg,** H. Albrecht, V. Knospe, A. Stoehr and J. van Lutstien, University or!Iambi. g, 11.t1sburg; P Goebel, Uuivetsky of Munich, N1u nicf.; *'11n. Nedset,usds:* S. Da •t and J. van den I *loin,* Academic Medical Centre, Auutenl.ou; and M. Thomson and **J.** Henderson, Syntex Development Research, Maidenhead, England.